Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 184

1.

Quantitative analysis of the anti-proliferative activity of combinations of selected iron-chelating agents and clinically used anti-neoplastic drugs.

Potuckova E, Jansova H, Machacek M, Vavrova A, Haskova P, Tichotova L, Richardson V, Kalinowski DS, Richardson DR, Simunek T.

PLoS One. 2014 Feb 20;9(2):e88754. doi: 10.1371/journal.pone.0088754. eCollection 2014.

2.

Methyl and ethyl ketone analogs of salicylaldehyde isonicotinoyl hydrazone: novel iron chelators with selective antiproliferative action.

Macková E, Hrušková K, Bendová P, Vávrová A, Jansová H, Hašková P, Kovaříková P, Vávrová K, Simůnek T.

Chem Biol Interact. 2012 May 30;197(2-3):69-79. doi: 10.1016/j.cbi.2012.03.010. Epub 2012 Apr 11.

PMID:
22521999
5.

Iron chelators as anti-neoplastic agents: current developments and promise of the PIH class of chelators.

Lovejoy DB, Richardson DR.

Curr Med Chem. 2003 Jun;10(12):1035-49. Review.

PMID:
12678675
6.

Novel aroylhydrazone and thiosemicarbazone iron chelators with anti-malarial activity against chloroquine-resistant and -sensitive parasites.

Walcourt A, Loyevsky M, Lovejoy DB, Gordeuk VR, Richardson DR.

Int J Biochem Cell Biol. 2004 Mar;36(3):401-7.

PMID:
14687919
8.

Identification of the di-pyridyl ketone isonicotinoyl hydrazone (PKIH) analogues as potent iron chelators and anti-tumour agents.

Becker EM, Lovejoy DB, Greer JM, Watts R, Richardson DR.

Br J Pharmacol. 2003 Mar;138(5):819-30.

9.

Structure-activity relationships of novel salicylaldehyde isonicotinoyl hydrazone (SIH) analogs: iron chelation, anti-oxidant and cytotoxic properties.

Potůčková E, Hrušková K, Bureš J, Kovaříková P, Špirková IA, Pravdíková K, Kolbabová L, Hergeselová T, Hašková P, Jansová H, Macháček M, Jirkovská A, Richardson V, Lane DJ, Kalinowski DS, Richardson DR, Vávrová K, Šimůnek T.

PLoS One. 2014 Nov 13;9(11):e112059. doi: 10.1371/journal.pone.0112059. eCollection 2014.

10.

Antitumor activity and mechanism of action of the iron chelator, Dp44mT, against leukemic cells.

Noulsri E, Richardson DR, Lerdwana S, Fucharoen S, Yamagishi T, Kalinowski DS, Pattanapanyasat K.

Am J Hematol. 2009 Mar;84(3):170-6. doi: 10.1002/ajh.21350.

11.
13.

Variable inhibitory effects on the formation of dinitrosyl iron complexes by deferoxamine and salicylaldehyde isonicotinoyl hydrazone in K562 cells.

Meczynska S, Lewandowska H, Sochanowicz B, Sadlo J, Kruszewski M.

Hemoglobin. 2008;32(1-2):157-63. doi: 10.1080/03630260701699821.

PMID:
18274993
14.

Methemoglobin formation by triapine, di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone (Dp44mT), and other anticancer thiosemicarbazones: identification of novel thiosemicarbazones and therapeutics that prevent this effect.

Quach P, Gutierrez E, Basha MT, Kalinowski DS, Sharpe PC, Lovejoy DB, Bernhardt PV, Jansson PJ, Richardson DR.

Mol Pharmacol. 2012 Jul;82(1):105-14. doi: 10.1124/mol.112.078964. Epub 2012 Apr 16.

15.
16.

A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics.

Whitnall M, Howard J, Ponka P, Richardson DR.

Proc Natl Acad Sci U S A. 2006 Oct 3;103(40):14901-6. Epub 2006 Sep 26.

17.

Bp44mT: an orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy.

Yu Y, Suryo Rahmanto Y, Richardson DR.

Br J Pharmacol. 2012 Jan;165(1):148-66. doi: 10.1111/j.1476-5381.2011.01526.x.

18.

Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.

Ikeda H, Taira N, Nogami T, Shien K, Okada M, Shien T, Doihara H, Miyoshi S.

Cancer Sci. 2011 Nov;102(11):2038-42. doi: 10.1111/j.1349-7006.2011.02050.x. Epub 2011 Sep 1.

19.

Synthesis and characterization of quinoline-based thiosemicarbazones and correlation of cellular iron-binding efficacy to anti-tumor efficacy.

Serda M, Kalinowski DS, Mrozek-Wilczkiewicz A, Musiol R, Szurko A, Ratuszna A, Pantarat N, Kovacevic Z, Merlot AM, Richardson DR, Polanski J.

Bioorg Med Chem Lett. 2012 Sep 1;22(17):5527-31. doi: 10.1016/j.bmcl.2012.07.030. Epub 2012 Jul 15.

PMID:
22858101
20.

Supplemental Content

Support Center